The efficacy of ALK inhibitors in cells harbouring point mutations in ALK was first demonstrated in a screen of 602 cancer cell lines with TAE684, a highly selective compound previously shown to inhibit the NPM-ALK fusion oncoprotein in ALCL [62,88]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.